Search results
Results from the WOW.Com Content Network
CA 27.29 is a tumor marker for breast cancer. [1] It is a form of glycoprotein MUC1. [2] References This page was last edited on 4 ... Code of Conduct; Developers;
Immunohistochemistry for CK7 of a metastatic undifferentiated carcinoma to a lymph node. Because the keratin-7 antigen is found in both healthy and neoplastic cells, antibodies to CK7 can be used in immunohistochemistry to distinguish ovarian and transitional cell carcinomas (staining positive) from colonic and prostate cancers (negative), respectively.
Tumor marker Associated tumor types Alpha fetoprotein (AFP) germ cell tumor, hepatocellular carcinoma [9] CA15-3: breast cancer [10] CA27.29: breast cancer [11] CA19-9: Mainly pancreatic cancer, but also colorectal cancer and other types of gastrointestinal cancer. [12] CA-125
Lobular neoplasia is considered pre-cancerous, and LCIS is an indicator (marker) for increased risk of developing invasive breast cancer in women. This risk extends more than 20 years. Most of the risk relates to subsequent invasive ductal carcinoma rather than to invasive lobular carcinoma. [4]
Scientists study the behaviour of isolated cells grown in the laboratory for insights into how cells function in the body in health and disease. Experiments using cell culture are used for developing new diagnostic tests and new treatments for diseases. This is a list of major breast cancer cell lines that are primarily used in breast cancer ...
Atypical ductal hyperplasia (ADH) is the term used for a benign lesion of the breast that indicates an increased risk of breast cancer. [1]The name of the entity is descriptive of the lesion; ADH is characterized by cellular proliferation (hyperplasia) within one or two breast ducts and (histomorphologic) architectural abnormalities, i.e. the cells are arranged in an abnormal or atypical way ...
The search engine that helps you find exactly what you're looking for. Find the most relevant information, video, images, and answers from all across the Web.
CA 27.29 has enhanced sensitivity and specificity compared to CA 15-3 and is elevated in 30% of patients with low-stage disease and 60 to 70% of patients with advanced-stage breast cancer. CA 27.29 levels over 100 U/mL and CA 15-3 levels over 25 U/mL are rare in benign conditions and suggest malignancy.